(Q37959316)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Potential use of statins in the treatment of antiphospholipid syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Antonio Rodriguez-Ariza

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Patricia Ruiz-Limon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Angeles Aguirre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maria José Cuadrado

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

Current Rheumatology Reports

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

87-94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11926-011-0222-6

17 January 2020

exact match

0 references

cites work

Antiphospholipid syndrome: pathogenic mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Antiphospholipid antibodies: lessons from the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

The role of tissue factor in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Systemic antiphospholipid syndrome and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Placentation, antiphospholipid syndrome and pregnancy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Synthesis of beta2 glycoprotein 1 by the human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pleiotropic effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Atherosclerotic disease regression with statins: studies using vascular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Twenty years of two-dimensional electrophoresis: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Statins for the treatment of antiphospholipid syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Simvastatin has deleterious effects on human first trimester placental explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Inhibition of HMG CoA reductase reveals an unexpected role for cholesterol during PGC migration in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-011-0222-6

Antiphospholipid antibodies in acute coronary syndrome

21 January 2018

1 reference

12 December 2020

Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial

1 reference

12 December 2020

Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels

1 reference

12 December 2020

Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-

1 reference

12 December 2020

Systemic endothelial cell markers in primary antiphospholipid syndrome

1 reference

12 December 2020

Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

1 reference

12 December 2020

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

12 December 2020

Autoantibodies associated with atherosclerosis

1 reference

12 December 2020

Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome

1 reference

12 December 2020

Statins and blood coagulation

1 reference

12 December 2020

New nonlipid effects of statins and their clinical relevance in cardiovascular disease

1 reference

12 December 2020

Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome

1 reference

12 December 2020

NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies.

1 reference

12 December 2020

Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases.

1 reference

12 December 2020

Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.

1 reference

12 December 2020

Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin

1 reference

12 December 2020

10.1007/S11926-011-0222-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105548%20AND%20SRC:MED&resulttype=core&format=json

release_msrkolleavcvrghhw2f6xik7pa

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/msrkolleavcvrghhw2f6xik7pa

24 November 2022

mapped directly with Wikidata item

1 reference